These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 36906630)

  • 1. Natural IgG antibodies to β amyloid are decreased in patients with Parkinson's disease.
    Paganelli R; Paganelli A; Pawelec G; Di Iorio A
    Immun Ageing; 2023 Mar; 20(1):13. PubMed ID: 36906630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naturally Occurring Autoantibodies against Tau Protein Are Reduced in Parkinson's Disease Dementia.
    Kronimus Y; Albus A; Balzer-Geldsetzer M; Straub S; Semler E; Otto M; Klotsche J; Dodel R; ; Mengel D
    PLoS One; 2016; 11(11):e0164953. PubMed ID: 27802290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amyloid-Beta Peptides Trigger Aggregation of Alpha-Synuclein In Vitro.
    Köppen J; Schulze A; Machner L; Wermann M; Eichentopf R; Guthardt M; Hähnel A; Klehm J; Kriegeskorte MC; Hartlage-Rübsamen M; Morawski M; von Hörsten S; Demuth HU; Roßner S; Schilling S
    Molecules; 2020 Jan; 25(3):. PubMed ID: 32013170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases.
    Hashimoto M; Rockenstein E; Crews L; Masliah E
    Neuromolecular Med; 2003; 4(1-2):21-36. PubMed ID: 14528050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.
    Dinda B; Dinda M; Kulsi G; Chakraborty A; Dinda S
    Eur J Med Chem; 2019 May; 169():185-199. PubMed ID: 30877973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.
    Atsmon-Raz Y; Miller Y
    ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. α-synuclein reactive antibodies as diagnostic biomarkers in blood sera of Parkinson's disease patients.
    Yanamandra K; Gruden MA; Casaite V; Meskys R; Forsgren L; Morozova-Roche LA
    PLoS One; 2011 Apr; 6(4):e18513. PubMed ID: 21541339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients.
    Lashley T; Holton JL; Gray E; Kirkham K; O'Sullivan SS; Hilbig A; Wood NW; Lees AJ; Revesz T
    Acta Neuropathol; 2008 Apr; 115(4):417-25. PubMed ID: 18185940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D; Biscetti L; Eusebi P; Salvadori N; Frattini G; Simoni S; De Roeck N; Tambasco N; Stoops E; Vanderstichele H; Engelborghs S; Mollenhauer B; Calabresi P; Parnetti L
    Alzheimers Res Ther; 2017 Jul; 9(1):52. PubMed ID: 28750675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-amyloid, phospho-tau and alpha-synuclein deposits similar to those in the brain are not identified in the eyes of Alzheimer's and Parkinson's disease patients.
    Ho CY; Troncoso JC; Knox D; Stark W; Eberhart CG
    Brain Pathol; 2014 Jan; 24(1):25-32. PubMed ID: 23714377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-Abeta component of Alzheimer's disease amyloid (NAC) revisited. NAC and alpha-synuclein are not associated with Abeta amyloid.
    Culvenor JG; McLean CA; Cutt S; Campbell BC; Maher F; Jäkälä P; Hartmann T; Beyreuther K; Masters CL; Li QX
    Am J Pathol; 1999 Oct; 155(4):1173-81. PubMed ID: 10514400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia.
    Bibl M; Mollenhauer B; Esselmann H; Lewczuk P; Klafki HW; Sparbier K; Smirnov A; Cepek L; Trenkwalder C; Rüther E; Kornhuber J; Otto M; Wiltfang J
    Brain; 2006 May; 129(Pt 5):1177-87. PubMed ID: 16600985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-beta uptake by blood monocytes is reduced with ageing and Alzheimer's disease.
    Chen SH; Tian DY; Shen YY; Cheng Y; Fan DY; Sun HL; He CY; Sun PY; Bu XL; Zeng F; Liu J; Deng J; Xu ZQ; Chen Y; Wang YJ
    Transl Psychiatry; 2020 Dec; 10(1):423. PubMed ID: 33293506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extending the functional characteristics of naturally occurring autoantibodies against β-Amyloid, Prion Protein and α-Synuclein.
    Albus A; Gold M; Bach JP; Burg-Roderfeld M; Jördens M; Kirchhein Y; Kronimus Y; Mengel D; Zerr I; Dodel R
    PLoS One; 2018; 13(8):e0202954. PubMed ID: 30157279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insights into the Molecular Mechanisms of Alzheimer's and Parkinson's Diseases with Molecular Simulations: Understanding the Roles of Artificial and Pathological Missense Mutations in Intrinsically Disordered Proteins Related to Pathology.
    Coskuner-Weber O; Uversky VN
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29364151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alpha-synuclein accumulates in Lewy bodies in Parkinson's disease and dementia with Lewy bodies but not in Alzheimer's disease beta-amyloid plaque cores.
    Bayer TA; Jäkälä P; Hartmann T; Havas L; McLean C; Culvenor JG; Li QX; Masters CL; Falkai P; Beyreuther K
    Neurosci Lett; 1999 May; 266(3):213-6. PubMed ID: 10465711
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.
    Tsigelny IF; Crews L; Desplats P; Shaked GM; Sharikov Y; Mizuno H; Spencer B; Rockenstein E; Trejo M; Platoshyn O; Yuan JX; Masliah E
    PLoS One; 2008 Sep; 3(9):e3135. PubMed ID: 18769546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aβ, Tau, and α-Synuclein aggregation and integrated role of PARK2 in the regulation and clearance of toxic peptides.
    Kumar D; Kumar P
    Neuropeptides; 2019 Dec; 78():101971. PubMed ID: 31540705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The contribution of beta-amyloid to dementia in Lewy body diseases: a 1-year follow-up study.
    Biundo R; Weis L; Fiorenzato E; Pistonesi F; Cagnin A; Bertoldo A; Anglani M; Cecchin D; Antonini A
    Brain Commun; 2021; 3(3):fcab180. PubMed ID: 34458730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.